Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.

Pharmaceutical

Catalyst Pharmaceuticals

Patrick J. McEnany 

Gary Ingenito

Jeff Del Carmen

Preethi Sundaram

Steven R. Miller

Alicia Grande

Brian Elsbernd

The Board and Governance team at Catalyst Pharmaceuticals is responsible for overseeing the company's strategic direction, ensuring compliance with regulatory requirements, and maintaining corporate governance standards. This team comprises experienced leaders who provide guidance and support to executive management, promoting transparency and accountability while driving the company's mission to develop innovative treatments for rare diseases. Their collective expertise fosters stakeholder confidence and contributes to the organization's long-term success.

Board and Governance

Medical Affairs and Patient Advocacy

Leadership Team

Board and Governance

About

Team members

Other teams at Catalyst Pharmaceuticals

Medical Affairs and Patient Advocacy

Leadership Team